{
    "ticker": "KPTI",
    "name": "Karyopharm Therapeutics Inc.",
    "description": "Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel therapies for the treatment of cancer and other serious diseases. Founded in 2008, Karyopharm is based in Newton, Massachusetts, and leverages its proprietary SINE (Selective Inhibitor of Nuclear Export) technology platform to create innovative drugs that target the nuclear export process in cells. The company\u2019s lead product candidate, Xpovio (selinexor), is an oral SINE compound that has been shown to inhibit the export of tumor suppressor proteins and other key molecules from the nucleus to the cytoplasm, thereby restoring their function and promoting cancer cell death. Karyopharm is committed to bringing its therapies to patients in need and has several ongoing clinical trials to evaluate the efficacy of its products in various hematological malignancies and solid tumors. In addition to Xpovio, Karyopharm has a robust pipeline of other SINE compounds aimed at treating different types of cancer and potentially other diseases. The company aims to improve patient outcomes through innovative research and development, and it collaborates with various academic and industry partners to enhance its product offerings.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology"
    ],
    "headquarters": "Newton, Massachusetts, USA",
    "founded": "2008",
    "website": "https://www.karyopharm.com",
    "ceo": "Michael G. Kauffman",
    "social_media": {
        "twitter": "https://twitter.com/Karyopharm",
        "linkedin": "https://www.linkedin.com/company/karyopharm-therapeutics/"
    },
    "investor_relations": "https://investors.karyopharm.com",
    "key_executives": [
        {
            "name": "Michael G. Kauffman",
            "position": "CEO"
        },
        {
            "name": "Megan R. H. L. Kelly",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology",
            "products": [
                "Xpovio (selinexor)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Karyopharm Therapeutics Inc. | Innovative Cancer Therapies",
        "meta_description": "Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on developing novel cancer therapies using its proprietary SINE technology. Explore Karyopharm's innovative drugs and commitment to patient care.",
        "keywords": [
            "Karyopharm",
            "Cancer Treatment",
            "Xpovio",
            "Oncology",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What is Karyopharm Therapeutics known for?",
            "answer": "Karyopharm Therapeutics is known for its innovative cancer therapies, particularly its lead product candidate Xpovio."
        },
        {
            "question": "Who is the CEO of Karyopharm Therapeutics?",
            "answer": "Michael G. Kauffman is the CEO of Karyopharm Therapeutics Inc."
        },
        {
            "question": "Where is Karyopharm headquartered?",
            "answer": "Karyopharm is headquartered in Newton, Massachusetts, USA."
        },
        {
            "question": "What is Xpovio?",
            "answer": "Xpovio (selinexor) is an oral SINE compound developed by Karyopharm for the treatment of various cancers."
        },
        {
            "question": "When was Karyopharm founded?",
            "answer": "Karyopharm was founded in 2008."
        }
    ],
    "competitors": [
        "BMY",
        "AMGN",
        "MRNA",
        "NVS"
    ],
    "related_stocks": [
        "GILD",
        "VRTX",
        "REGN",
        "ABBV"
    ]
}